Alpha Cognition Inc. · NASDAQ:ACOG
Alpha Cognition — Investor Presentation (January 2025)
23 slides from Alpha Cognition's investor presentation, January 2025
Slide 1: Bringing Hope to People Living with Neurodegenerative Diseases
BRINGING HOPE TO PEOPLE LIVING WITH NEURODEGENERATIVE DISEASES Corporate Presentation, January 2025 www.alphacognition.com
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation has been prepared by Alpha Cognition Inc. (“ACI” or the “Company”). This presentation includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this present
Slide 3: ZUNVEYL Has Received FDA Approval to Treat Alzheimer's Disease
ALPHA COGNITION’S ORAL THERAPY ZUNVEYL HAS RECEIVED FDA APPROVAL TO TREAT ALZHEIMER'S DISEASE The Second Oral Therapy Approved This Decade, ZUNVEYL’s Dual MOA Was Designed to Minimize Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading
Slide 4: Commercial & R&D Biopharmaceutical Company Focused on Neurodegenerative Diseases
COMMERCIAL & R&D BIOPHARMACEUTICAL COMPANY FOCUSED ON NEURODEGENERATIVE DISEASES ZUNVEYL® – Differentiated Treatment Potential for ALZHEIMER’S DISEASE • Large US 11M annual prescription (Rx) market characterized by high drug dissatisfaction and discontinuation1 • Oral therapy uniquely designed to re
Slide 5: Alzheimer's Disease Has Significant Treatment Challenges and High Drug Discontinuation
ALZHEIMER’S DISEASE HAS SIGNIFICANT TREATMENT CHALLENGES AND HIGH DRUG DISCONTINUATION ALZHEIMER’S DISEASE (AD) is a type of dementia that causes a slow decline in memory, thinking and reasoning. AD therapy represents a significant US market with high dissatisfaction, primarily due to adverse events
Slide 6: ZUNVEYL: Uniquely Designed Prodrug of Galantamine
ZUNVEYL: UNIQUELY DESIGNED PRODRUG OF GALANTAMINE The formation of the benzoyl ester eliminates AChE inhibition; the gluconate salt increases solubility Potential treatment ZUNVEYL is absorbed in the small designed to optimize intestine as an inactive compound with minimal or no side effects efficac
Slide 7: Galantamine Enhances Acetylcholine Levels & Modulates Nicotinic Receptor Sensitivity
GALANTAMINE (ZUNVEYL’S ACTIVE MOIETY) ENHANCES ACETYLCHOLINE LEVELS & MODULATES NICOTINIC RECEPTOR SENSITIVITY Decreased acetylcholine levels and loss of nicotinic acetylcholine receptors (nAChR) negatively impacts learning, memory, and function Current therapeutics1 increase acetylcholine levels by
Slide 8: Pivotal Trial Results Provided Data Enabling NDA Filing
PIVOTAL TRIAL RESULTS PROVIDED DATA ENABLING NDA FILING Bioequivalence Studies vs. Immediate Release Bioequivalence Study vs. Extended Release PK ALPHA-1062 Delayed Gal HBr Immediate % to Reference Drug Parameter Enabled NDA Filing Release 5mg (n=36) Release 4mg (n=36) 80-125% AUC0-inf (μg × h/mL) 3
Slide 9: Studies Have Reported Improved Gastrointestinal Side Effect Profile
STUDIES HAVE REPORTED IMPROVED GASTROINTESTINAL SIDE EFFECT PROFILE* Diarrhea Nausea, Vomiting 40 37.8 % of Subjects Reporting Gl Episode 35 30 25 20.0 20 15 10 8 9 5 2 1 0 ALPHA-1062 5-15mg RAZADYNE 8 mg/day RAZADYNE Pooled AE Data Single and Multi-Dose Trials Single Dose (Doses ranging 8 to 32 mg/
Slide 10: ZUNVEYL's Differentiated Profile Will Make a Meaningful Difference
ZUNVEYL’s differentiated profile will make a meaningful difference in the lives of those affected by Alzheimer’s disease Designed to minimize absorption in the stomach to avoid stimulation of the GI nervous system Purposefully Designed GALANTAMINE RIVASTIGMINE DONEPEZIL Prodrug Technology Protects f
Slide 11: ZUNVEYL Designed to Eliminate Drug Absorption in the GI Tract, Zero Insomnia
ZUNVEYL WAS DESIGNED TO ELIMINATE DRUG ABSORPTION IN THE GI TRACT AND HAS ZERO INCIDENCE OF INSOMNIA ZUNVEYL Delayed Released Tablets 0% incidence of insomnia in ZUNVEYL label Enteric coat: dissolves in small intestine • Enteric coat designed to pass Subcoat: dissolves after enteric coat through the
Slide 12: Galantamine Reduces Risk of Disease Progression & Has Strongest Effect on Cognition
GALANTAMINE (ZUNVEYL’S ACTIVE MOIETY) REDUCES RISK OF DISEASE PROGRESSION & HAS THE STRONGEST EFFECT ON COGNITION Galantamine affects multiple brain receptors to exert effect Galantamine has demonstrated anti-inflammation effects1 Galantamine has been associated with:1,2 Improved Significantly Stron
Slide 13: Many Successful Drug Launches for Alzheimer's Indicate Need for New Treatments
MANY SUCCESSFUL DRUG LAUNCHES FOR ALZHEIMER’S TREATMENT INDICATE NEED FOR NEW AND IMPROVED TREATMENTS Exelon Follow-On (Oral to GI-Bypassing Patch) Peak Sales (in B)1 $700.00 $600.00 $2.6 $500.00 $400.00 $300.00 $1.8 $200.00 $1.25 $100.00 $- $0.650 Oral Patch $0.270 $0.250 Large US 11M annual prescr
Slide 14: Namzaric 505(b)(2) Treatment Delivers +$200M in Yearly Sales
DESPITE NO DIFFERENTIATION, NAMZARIC, 505(B)(2) TREATMENT FOR MODERATE-TO-SEVERE ALZHEIMER’S DELIVERS +$200M IN YEARLY SALES NAMZARIC provides base case for sales for a new NAMZARIC Sales by Year ($M) symptomatic entrant into the Alzheimer’s (AD) market $300 $267 505(b)(2) pathway with no differenti
Slide 15: AChEI Market Large but Dissatisfied, Specifically in Long Term Care
ACHEI’S MARKET LARGE BUT DISSATISFIED CREATING OPPORTUNITY FOR IMPROVED TREATMENT OPTION, SPECIFICALLY IN LONG TERM CARE (LTC) Large, but dissatisfied market creates significant market opportunity Prescriptions by Specialty1 11M AChEI RX’s dispensed each year1 High discontinuation rates due to side-
Slide 16: Alzheimer's Dementia Affects 70% of LTC Residents & 88% of LTC Doctors Likely to Prescribe
ALZHEIMER’S DEMENTIA AFFECTS 70% LONG TERM CARE (LTC) RESIDENTS & 88% LTC DOCTORS LIKELY TO PRESCRIBE Large, Underserved LTC Market In Nursing Homes, Alzheimer’s Dementia: 6.7M Affects Is the leading Is the leading 5.4M 1.2M 70% residents1 reason for placement1 cause of death1 Significant Dissatisfa
Slide 17: Commercialization Strategy Will Leverage LTC Experience & Focused Sales Effort
COMMERCIALIZATION STRATEGY WILL LEVERAGE LTC EXPERIENCE & FOCUSED SALES EFFORT AT LAUNCH 33 Person Commercial Team Target largest Covers >80% of the LTC Segment geographies with highest concentration of LTC lives 726 – 9K 11K – 23K 24K – 35K 40K – 99K Experienced, account-based sales team with demon
Slide 18: ZUNVEYL Alzheimer's Dementia Opportunity
ZUNVEYL ALZHEIMER'S DEMENTIA OPPORTUNITY Large but Dissatisfied Market Additional Development • LTC represents largest Programs AD prescription volume • ZUNVEYL sublingual tablet • >50% discontinue treatment formulation and pharmacokinetic work at 12 months • 88% LTC HCPs potentially • ALPHA-1062 pr
Slide 19: Alpha Cognition Clinical Pipeline
ALPHA COGNITION CLINICAL PIPELINE Preclinical Phase 1 Phase 2 Phase 3 /Pivotal Approved 2025 Alzheimer’s Dementia Advancement Oral: Mild-to-Moderate Alzheimer’s Disease (AD) Sublingual Formulation: Complete Formulation Mild-to-Moderate and pharmacokinetic Alzheimer’s Disease (AD) studies Moderate-to
Slide 20: Potential Catalysts and Upcoming Events
POTENTIAL CATALYSTS AND UPCOMING EVENTS ZUNVEYL pricing determination (Q1) ZUNVEYL commercial launch (Q1) DOD Sponsored Pre-clinical Bomb-blast results, final (Q2) 2025 Sublingual formulation completion (Q4) Acute Pancreatitis proof-of-concept preclinical study completion (Q4) Sublingual pharmacokin
Slide 21: Leadership Has Impressive Track Record for Drug Development & Commercialization
Leadership Has Impressive Track Record For Successful New Drug Development & Commercialization 30+ years in drug discovery & 25+ years in pharmaceuticals commercialization (16+ years in Neuroscience) marketing, sales, and operations Michael McFadden Lauren D’Angelo, MBA Former COO at MPower Health a
Slide 22: Share Capitalization
Share Capitalization NASDAQ: ACOG Issued and December 30, 2024 Outstanding % of Total Common Shares 16,019,787 76.2% Issued & Proforma % of total Outstanding Outstanding 1 Class B Preferred Series A Shares 316,655 1.5% 150,855,536 56.7% 6,034,221 Performance Shares 7,916,380 2.9% 265,642 316,655 1.3
Slide 23: Investor Relations
Investor Relations info@alphacognition.com www.Alphacognition.com x.com/alpha_cognition Copyright 2024 Alpha Cognition | Legal
Alpha Cognition — Investor Presentation (January 2025) on 6ix